Side-by-side · Research reference

GHK-CuvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED8/47 cited

BPhase 3HUMAN-REVIEWED9/42 cited

GHK-Cu

Tripeptide · Skin / Hair / Wound Healing

1–2 mgSQ dosePickart 2018

HumanMechanisticPickart 2018 Zink 2003

HoursHalf-life

SQ or topical · Local · Daily or 2-3×/week

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

GHK-Cu

VIP

Primary target

Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018 Zink 2003

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Replaces declining endogenous levels

Yes — exogenous VIP acts as physiological agonist

Origin

Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

GHK-Cu

VIP

Standard SQ dose

1–2 mg / dayPickart 2018

Anecdotal injectable range; topical creams use 0.1–2% solutions.

—

Topical concentration

0.1–2.0% in serum / cream

—

Frequency

Daily or 2–3× per week (SQ)

—

Lower / starter dose

0.5 mg / day SQ

—

Evidence basis

Human-mechanistic + topical clinical studiesPickart 2018

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Duration

8–12 weeks for visible skin / hair effect

—

Reconstitution

Bacteriostatic water; light-protected

Lyophilized powder reconstituted with sterile diluent per protocol

Timing

No specific time; evening preferred for topicals

—

Half-life

Hours (estimated; rapid tissue uptake)

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

04Side Effects & Safety

Parameter

GHK-Cu

VIP

Injection site reaction

Erythema, mild pruritus (common)

—

Topical irritation

Mild redness, transient stinging

—

Copper accumulation

Theoretical with very high chronic doses

—

Allergic reaction

Rare hypersensitivity to copper

—

Pregnancy / OB

Avoid topical and SQ — insufficient data

—

Wilson disease

Contraindicated

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

GHK-Cu

·Wilson disease (copper-overload disorder)
·Pregnancy / breastfeeding
·Known copper hypersensitivity

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

GHK-Cu

·Hemochromatosis (copper-iron crosstalk theoretical)
·Concurrent copper-chelator therapy

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

GHK-Cu

VIP

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Anytime; evening preferred. Topical: apply to clean dry skin.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Needle

30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.

06Stack Synergy

GHK-Cu

+ BPC-157

Moderate

View BPC-157 →

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu: 1–2 mg SQ · daily near wound
BPC-157: 250–500 mcg SQ · daily near wound
Primary benefit: Combined ECM rebuilding + angiogenesis for tissue repair

VIP

— no documented stacks